Eversana sets first- and second-lien term loan price talk with launch

By Sara Rosenberg

New York, Nov. 9 – Eversana (LSCS Holdings Inc.) released price talk on its $690 million seven-year first-lien term loan and $290 million eight-year second-lien term loan with its lender call on Tuesday, according to a market source.

The first-lien term loan is talked at Libor plus 450 basis points to 475 bps with a 0.5% Libor floor and an original issue discount of 99, and the second-lien term loan is talked at Libor plus 775 bps to 800 bps with a 0.5% Libor floor and a discount of 98.5, the source said.

Included in the first-lien term loan is 101 soft call protection for six months, and the second-lien term loan has hard call protection of 102 in year one and 101 in year two.

The company’s $1.07 billion of credit facilities also provide for a $90 million five-year revolver.

Jefferies LLC, KeyBank Capital Markets and RBC Capital Markets are the bookrunners on the deal.

Commitments are due at noon ET on Nov. 19, the source added.

Proceeds will be used to fund the acquisition of Intouch Group.

Closing is expected by the end of the year.

Eversana is a provider of global services to the life sciences industry. Intouch is an agency network serving the pharmaceutical industry.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.